Caidya

Executive Summary

Caidya is a global, full-service Contract Research Organization (CRO) that partners with biopharmaceutical innovators to navigate clinical development complexities. Founded in 2019 and headquartered in San Francisco, the company offers flexible, patient-centric clinical trial solutions across diverse therapeutic areas. With a mission to deliver high-quality data and agile execution, Caidya supports clients from early-phase to Phase 2/3 trials. As a private company operating in the Diagnostics and Digital Health categories, Caidya leverages its global reach and deep therapeutic expertise to help bring life-changing therapies to patients. The CRO market is experiencing steady growth driven by increasing R&D outsourcing by pharma companies, and Caidya is well-positioned to capture market share through its focus on quality and flexibility. Key catalysts include potential major partnership announcements, expansion into high-growth therapeutic areas, and progress on client trial milestones that could lead to increased visibility and revenue.

Upcoming Catalysts (preview)

• Q3 2026Announcement of a major pharmaceutical partnership for a Phase 3 trial60% success
• Q2 2026Expansion into oncology or rare disease therapeutic areas via new client win50% success
• Q4 2026Client trial reaches primary endpoint with positive data readout, enhancing Caidya's reputation40% success